Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Nicotinic acetylcholine receptors as targets for antidepressants


While the monoamine deficiency hypothesis of depression is still most commonly used to explain the actions of antidepressant drugs, a growing body of evidence has accumulated that is not adequately explained by the hypothesis. This article draws attention to contributions from another apparently common pharmacological property of antidepressant medications—the inhibition of nicotinic acetylcholine receptors (nAChR). Evidence is presented suggesting the hypercholinergic neurotransmission, which is associated with depressed mood states, may be mediated through excessive neuronal nicotinic receptor activation and that the therapeutic actions of many antidepressants may be, in part, mediated through inhibition of these receptors. In support of this hypothesis, preliminary evidence is presented suggesting that the potent, centrally acting nAChR antagonist, mecamylamine, which is devoid of monoamine reuptake inhibition, may reduce symptoms of depression and mood instability in patients with comorbid depression and bipolar disorder. If this hypothesis is supported by further preclinical and clinical research, nicotinic acetylcholine receptor antagonists may represent a novel class of therapeutic agents for treating mood disorders.


Currently accepted hypotheses regarding the etiology of depression originated over 30 years ago following serendipitous clinical observations that monoamine-elevating medications improved mood in patients with depression. The pharmacological actions of these drugs formed the basis for the monoamine hypothesis of depression postulating a functional deficiency of monoaminergic neurotransmission in the affected brain. However, various anomalous findings and recent discoveries have led to consideration of alternative hypotheses regarding the mechanism of action of antidepressants. The purpose of the present article is to highlight another apparently common pharmacological characteristic of many antidepressant medications—the inhibition of nicotinic acetylcholine receptors (nAChR). Evidence will be presented suggesting that hypercholinergic neurotransmission, which is associated with depressed mood states, may be partially mediated through excessive activation of nAChR and that the therapeutic actions of many antidepressants may be, in part, mediated through inhibition of these receptors.

Limitations of the monoamine deficiency hypothesis of depression

The hypothesis that depression is associated with a relative deficiency of the monoamines, norepinephrine (NE) and serotonin (5-HT), which most antidepressants are known to elevate,1,2,3 continues to be widely held. However, evidence is growing which increasingly exposes the limitations of this hypothesis.4 For example, cerebral spinal fluid levels of 5-HT in unmedicated depressed patients have been reported to be elevated two-to-four times above levels in normal controls.5 The tryptophan hydroxylase activation inhibitor, AGN2979, which would be expected to reduce 5-HT levels, actually reduces depression clinically.6 Moreover, the clinically effective and marketed antidepressant, tianeptine, enhances the reuptake of 5-HT,7 the exact opposite effect of selective serotonin reuptake inhibitors (SSRIs). Finally, the potent centrally active monoamine reuptake inhibitor, EXP561, which was predicted to be superior to imipramine preclinically, was completely devoid of clinical antidepressant activity in humans.8 These findings do not support the hypothesis that depression is caused only by a deficiency of monoamines, in particular serotonin. In fact, some have even argued that enhanced NE and 5-HT levels induced by antidepressants may be responsible for their delayed onset of action, sexual dysfunction, and tendency to produce mania in patients predisposed to bipolarity.4

The anomalous findings outlined above, and the long standing recognition of the discordance between the rapid monoaminergic effects of antidepressants and their delayed therapeutic onset of action, have led to consideration of alternative hypotheses regarding the mechanism of action of antidepressants. For example, recent reports suggest that chronic antidepressant treatment produces neurotropic-like effects such as enhanced regeneration of catecholamine axon terminals in the cerebral cortex, enhanced hippocampal synaptic plasticity, and the attenuation of stress-induced atrophy of the hippocampal CA3 pyramidal neurons. These downstream neurotropic effects of antidepressants are thought to explain their delayed onset of action and ultimate therapeutic actions in the treatment of depression.9,10 Another recently proposed hypothesis maintains that therapeutic properties of antidepressants are primarily mediated through inhibition of neuronal potassium (K+) channels and subsequent interference with the stress-induced activation of tryptophan hydroxylase responsible for excessive elevations of 5-HT.4 While not discounting these potentially important effects of antidepressant drugs, it is also worthwhile to consider how other common pharmacological properties of antidepressants may contribute to their overall therapeutic mode of action. One such property shared by many antidepressants is the inhibition of nAChRs.

Antidepressants as nicotinic acetylcholine receptor antagonists

Over the past 20 years, several independent groups have reported on the nAChR inhibitory actions of classic tricyclic antidepressants including imipramine,11,12,13 nortriptyline, amitriptyline,14,15 and desipramine.13,16 More recent studies have characterized newer, more selective monoamine reuptake inhibitors including fluoxetine,17,18,19 sertraline, paroxetine, nefazodone,20 nisoxetine, citalopram, nomifensine,21 and GBR-1290922 as nAChR antagonists. Perhaps one of the most interesting antidepressants demonstrated to have nAChR inhibitory activity is the atypical antidepressant, bupropion.20,23,24 Bupropion is unique because it is a relatively weak reuptake inhibitor of both NE and DA, with little or no direct action on serotoninergic neurotransmission. Moreover, like the potent nicotinic receptor antagonist, mecamylamine,25,26 bupropion blocks the acute effects of nicotine in animals23 and is an effective smoking cessation drug (Zyban®).27

As shown in Table 1, the concentrations of antidepressants that inhibit nAChRs are consistently in the low micromolar range as reported from different laboratories employing different methodological approaches. While the prominent monoaminergic effects of these drugs occur at much lower concentrations, it has been argued that concentrations required to inhibit nAChRs are comparable to the antidepressant concentrations accumulated in the brain at about the time that these drugs begin to be therapeutically active.20,21 If antidepressants reduce depression, in part, through nAChR inhibition, the question remains as to how this might occur.

Table 1 Inhibition of nicotinic receptor function by various antidepressants and mecamylamine*

The cholinergic-adrenergic theory of depression

One of the most consistent findings in neuropsychiatry is that patients with depression have dysfunctional neuroendocrine systems possibly resulting from prolonged responses to stress.28,29 The available evidence suggests that acetylcholine (ACh) plays a significant role in mediating neuroendocrine, emotional, and physiological responses to stress. For example, central acetylcholine turnover is increased following stress30 and ACh facilitates the release of several stress-sensitive neurohormones and peptides including corticosterone, ACTH, and CRF.31

The cholinergic-adrenergic theory of depression hypothesizes a balance between cholinergic and adrenergic systems, suggesting that overactivity of the cholinergic system over the adrenergic system could lead to depressive symptoms.32 Consistent with this hypothesis, strong evidence supports the presence of exaggerated responses (behavioral, neurochemical, sleep) to cholinergic agents in affective disorder patients relative to controls.33 For example, the indirect ACh agonist, physostigmine, when administered to normal subjects, causes an increase in heart rate and blood pressure and produces symptoms of dysphoria, depression, anxiety, irritability, aggressiveness and hostility. When physostigmine was administered to patients with affective disorders, the symptoms of negative affect were more pronounced and longer lasting.31,34 Depression-like symptoms have also been observed in normal subjects receiving i.v. physostigmine or arecoline,35,36 and physostigmine was reported to induce depression in a majority of euthymic bipolar patients maintained on lithium.37

Cholinergic hyperactivity or hypersensitivity may also be a marker for an affective disorder or of a genetic predisposition to develop an affective disorder.38 Using in vivo hydrogen magnetic resonance spectroscopy, Charles et al (1994) observed an increase in central choline, the rate-limiting precursor to acetylcholine, in the brains of depressed patients relative to normal controls.39 In addition, a recent study using similar techniques found increased orbitofrontal cortex levels of choline in depressed adolescents in comparison with control subjects.40

The cholinergic-adrenergic theory of depression was postulated in the 1970s and 1980s when more was known about muscarinic than nicotinic ACh receptors. While much more is now known about nicotinic receptor neuropharmacology, few attempts have been made to adequately explain the role nicotinic receptors play in the context of the cholinergic-adrenergic theory of depression. However, it is now known that the neuroendocrine effects of physostigmine are mediated primarily through activation of nAChRs, not muscarinic receptors.41,42 In addition, studies characterizing the effects of smoking on mood throughout the day in normal smokers suggest that while mood improves immediately after smoking, mood impairments (ie irritability and depression) occur between cigarettes.43 This repetitive cycle of shifting mood suggests a role for nicotinic receptors in mood regulation and may partially explain the high prevalence of smoking in patients with affective disorders.44

Nicotine and depression

Nicotine dependence is the single most common psychiatric diagnosis in the United States, and major depression, anxiety disorders, and substance abuse are the most prevalent psychiatric comorbid conditions associated with nicotine dependence.45 The prevalence of nicotine dependence in patients with major depression ranges from 50–60%.44,46 Smokers with a history of major depression are also two to three times more likely to have failed smoking cessation attempts compared to dependent smokers without a history of major depression.47 Moreover, ex-smokers with a history of depression appear to be at substantial risk for the emergence of depressive symptom exacerbation, generally within one month of smoking cessation.44,48 In addition, clinically significant symptoms of mania and depression have been reported following smoking cessation in some individuals,49 and transdermal nicotine was reported to rapidly reduce depression in nonsmoking depressed patients.50 These findings, along with preclinical evidence that nicotine has antidepressant properties in animal models of depression51,52,53,54 and that ‘knock-out’ mice which lack the prominent β2-nAChR subunit are more prone to learned helplessness,55 emphasize the strong relationship between nicotinic receptor modulation and mood control.

An unresolved problem in the established association between depression and smoking is the issue of causality, since the potential for self-medication or precipitation of depression on cessation is inherent in the modulating effects of nicotine and non-nicotine constituents of tobacco smoke on neurotransmitter systems.45 While there is evidence to support the notion that depressed smokers self-medicate by smoking,56,57,58 other evidence suggests that smoking, particularly during adolescence, increases the risk of developing depression later in life.59,60,61 Still, other studies have suggested that common genetic factors may contribute to both smoking and major depression without one causing the other.62

Conflicting evidence regarding the relationship between nicotine and mood control might be explained by considering nicotine's complex neuropharmacology and the distribution of nicotinic receptors in neural circuits regulating responses to stress, the circadian rhythm, and behavioral reinforcement. There also is the possibility that nicotine exposure alters mood control circuitry in a state-dependent manner as has been reported for other pharmacological actions of nicotine.63 Thus, chronic nicotine exposure might enhance the risk of mood instability in those with a stable mood baseline or stabilize mood in individuals with pre-existing mood instability. Figure 1 illustrates plausible state-dependent effects of nicotine on mood.

Figure 1

State-dependent effects of nicotine. (a) Illustration of nicotine's state-dependent effects where the baseline mood state determines the affective response to nicotine. (b) Illustration of nicotine's state-dependent therapeutic effects where nicotine ultimately stabilizes mood in persons with affective disorders.

Nicotinic acetylcholine receptors and their distribution

Cholinergic neurons originate mainly in the basal forebrain and the diagonal band region of the reticular formation and are known to project and innervate widely into various regions of the brain.64,65 The cholinergic system arising from the basal forebrain makes broad projections mainly throughout the cortex and hippocampus. A second major cholinergic system arises in the pedunculopontine tegmentum and the laterodorsal pontine tegmentum, providing widespread innervation mainly to the thalamus and midbrain areas and also descending innervation to the brain stem. Overall, a relatively few cholinergic neurons make spare projections that cover broad areas. Therefore, the activity of a rather small number of cholinergic neurons can modulate relatively large neuronal systems.

Nicotinic acetylcholine receptors belong to a superfamily of ligand-gated ion channels that exist in many different subtypes constructed from a myriad of possible subunit combinations.64,65 These receptors are composed of five subunits that are assembled to form an ion channel, which opens when a ligand binds to a particular recognition site(s). While sodium and potassium ions compose most of the nAChR current, calcium can also make a significant contribution. The properties of a receptor can be modified depending on what subunits are included in the final receptor, a feature common to most families of ligand-gated ion channels. Eleven genes cloned from the nervous system code for nAChR subunits, which include eight proteins designated as alpha subunits (α2–α9) and three proteins designated as beta subunits (β2–β4).65,66,67,68 Most nicotinic receptors found in the nervous system require at least one type of alpha and one type of beta subunit to form functional nAChR channels. However, there are homomeric nicotinic receptors that contain five identical alpha subunits. This structural diversity coupled with the axonal, presynaptic, and postsynaptic locations of nAChRs contribute to the various roles these receptors play in both synaptic and volumetric neurotransmission throughout the central nervous system.64,69,70 Presynaptic nAChRs modulate the release of monoamines as well as GABA, glutamate, and various neuropeptides.65 These characteristics along with broad cholinergic innervation throughout the brain ensure that nAChRs are important modulators of neuronal excitability.

Nicotinic receptor activation appears to be short-lived, and time-dependent decreases in functional responsiveness to acute nicotinic agonist challenge develop with prolonged agonist exposure.64,71 A reversible (within minutes) loss of nAChR function induced after seconds-minutes of agonist exposure is termed ‘desensitization.’ More prolonged exposure to agonist can lead to more slowly reversible phases of loss of nAChR responsiveness termed ‘persistent inactivation,’ at least for some nAChR subtypes.65 These phases of desensitization and persistent inactivation add complexity to the understanding of the effects of nicotinic agonists on nAChR function and similarly complicate understanding the possible role of nicotinic receptors in the regulation of mood. Further complicating matters, degrees of nAChR activation, desensitization and persistent inactivation are subtype-, time-, and dose-dependent, reflecting both form and route of administration (bolus vs continuous), influences that make it difficult to extricate roles of nAChR in mood control.64,72 Long exposures to low concentrations of agonist will favor deeper levels of desensitization, and this situation is often the case for smokers, who maintain low concentrations of nicotine throughout the day.71,73,74,75 With this in mind, it has been proposed that nicotine's predominant effect on many nAChR subtypes over time (its time-averaged effect) is that of an antagonist.76 However, some nAChR subtypes are more resistant to desensitization than others, and there is some evidence that certain receptor subtypes become more sensitive to repeated agonist exposure.72

The most abundant forms of nAChR in the mammalian brain contain either α4 and β2 subunits or α7 subunits.77,78 However, less abundant nAChR subtypes may play disproportionate roles in some brain functions, and there are some brain regions that have non-α7 and -α4β2 agonist and antagonist profiles. For example, both medial habenula and locus coeruleus neurons express nAChRs with a pharmacologic profile that is consistent with expression of nAChR containing α3 and β4 subunits,79 but relatively few β2-subunits are contained in medial habenular nAChRs.80 Another example is that α7-containing nAChRs mediate the predominant nicotinic current in hippocampal neurons, but other nAChR responses may be attributable to α4β2 and α3β4-containing, and other nAChRs.81,82 Nicotinic receptor α3, α6 and β3 subunits are enriched in midbrain nuclei associated with behavioral reinforcement.71,73,74,75

Role of nicotinic receptors and the hypothalamic-pituitary axis (HPA)

One of the most replicated findings in biological psychiatry is that large numbers of unmedicated depressed patients exhibit HPA hyperactivity.29 The available evidence suggests that nAChR play important roles in mediating stress-related and possibly depression-inducing neuroendocrine effects of ACh. For example, the nAChR antagonist, mecamylamine, has been found to block the physostigmine-induced rise in plasma corticosterone levels in rats.41,42 In addition, ACh-induced CRF release from the hypothalamus is inhibited by nAChR blockade,83 which is consistent with findings that nAChR receptors have been identified presynaptically on CRF producing neuron terminals.84

Involvement of nAChR during stress is implicated by the observation that chronic stress causes a downregulation of nAChR in the brain.85 Direct involvement of nicotinic receptor activation in contributing to the neuroendocrine responses to stress is supported by the finding that mecamylamine abolishes the plasma corticosterone response to auditory stress in rats86 and has anxiolytic properties in animal models.87 Physiologically, nicotinic receptor blockade reduces the effects of stress on cardiovascular function88 and inhibits emotionally conditioned presser responses in rats.89 Overall, these findings suggest that nicotine directly and certain stressors indirectly, via ACh, stimulate the hypothalamic-pituitary axis (HPA) through activation of nAChRs. Thus, antidepressants may reduce symptoms of depression, in part, through blockade of nAChRs involved with stress-induced activation of the HPA.

Nicotinic receptors and the mesolimbic dopamine system

Another role that nAChRs may play in regulating mood is through modulation of midbrain dopaminergic neurons. Nicotine is the primary component of tobacco that causes dependency, and like other addictive drugs, nicotine reinforces self-administration in animal studies.90,91 Considerable evidence suggests that midbrain dopamine neurons reinforce behavior leading to biologically rewarding events, but addictive drugs such as nicotine can inappropriately exert a reinforcing influence by activating the mesolimbic dopamine system.92 Recent studies suggest that the same concentration of nicotine achieved by smokers, activates and desensitizes multiple nicotinic receptors, thereby modulating the activity of mesolimbic dopamine neurons.93 Initial application of nicotine can increase the activity of the dopaminergic neurons, which could mediate the reinforcing and possibly acute antidepressant aspects of tobacco use. Prolonged exposure to even these low concentrations of nicotine, however, can cause desensitization of nAChRs, which helps to explain acute tolerance to nicotine's effects on mood. Thus, the mood altering effects of smoking may depend, in part, on the interplay between activation and desensitization of multiple nicotinic receptors modulating midbrain dopamine neurons. Likewise, antidepressants effective for smoking cessation may be efficacious, in part, through inhibiting the effects of nicotine on nAChRs localized on dopaminergic neurons. In this regard, it is noteworthy that bupropion (Zyban®) is relatively selective at inhibiting α3β2-nAChRs which have been implicated in nicotine-induced dopamine release from midbrain dopamine neurons.23

Nicotinic receptors and the circadian rhythm

Considerable evidence suggests a relationship between mood instability and disrupted circadian rhythm.94 While a role for cholinergic influences on the circadian system is clear, the extent to which these influences are mediated by nAChRs has been controversial, as have the specific actions of nicotine and acetylcholine in the suprachiasmatic nucleus (SCN) of the hypothalamus.95 However, new evidence suggests a regulatory role for nAChRs in both the developing and adult SCN.96 For example, a recent report of a significant increase in nAChR β2 subunit mRNA expression in the SCN during spontaneous waking and following sleep, deprivation relative to sleep, is the first demonstration of an activity-dependent regulation in the expression of this gene.97 Pharmacologically, nicotine is capable of causing phase shifts in the circadian rhythms of rats. Like light and carbachol, nicotine appears to cause phase delays in the early subjective night and phase advances in the late subjective night. Mecamylamine blocks these effects of nicotine, and mecamylamine alone blocks both the phase forward and phase delaying effects of light on the circadian rhythm.98,99 Nicotine's effect on nAChRs in the SCN might also contribute to the sleep problems which have been characterized in both adolescent and adult smoking populations.100,101

Preliminary clinical findings with mecamylamine

If antidepressants reduce depression, in part, through inhibition of nAChR, then one would expect antidepressant properties from a nAChR antagonist even in the absence of any effects on monoamine transporter function. Indeed, preliminary evidence suggests that the potent centrally acting nAChR antagonist, mecamylamine (Inversine®), which is devoid of monoamine reuptake inhibition, may reduce symptoms of depression and mood instability in patients with comorbid depression and bipolar disorder.102,103

We have previously proposed that the therapeutic effect of transdermal nicotine as an adjunct to neuroleptic treatment of Tourette's disorder104 may involve nAChR inactivation resulting from a prolonged continuous exposure to nicotine.105 In vitro studies with nicotine71 and preliminary positive clinical observations with mecamylamine in the clinical treatment of TD patients, further support the receptor inactivation hypothesis.106 Mecamylamine was originally used as a ganglionic blocker to treat hypertension with doses ranging from 25 to 90 mg day−1.107 However, more recent studies suggest that at lower doses (2.5–5 mg b.i.d.), mecamylamine functions as a potent centrally acting nAChR antagonist that may be useful for treating tobacco,26 cocaine108 and alcohol dependency.109 In addition, we reported an unexpected mood stabilizing response to mecamylamine in two Tourette's disorder (TD) patients who were subsequently found to have comorbid bipolar disorder as defined by DSM-IV criteria.102 To investigate the safety and efficacy of mecamylamine under more rigorous conditions, we recently conducted a multi-center double-blind placebo controlled study of mecamylamine monotherapy in children and adolescents diagnosed with TD who suffered predominately from behavioral and emotional symptoms.110 The results indicated that mecamylamine monotherapy was well tolerated, but no more effective than placebo for the treatment of tics. However, in patients with moderate to severe TD illness severity, mecamylamine treatment was associated with significant reductions in sudden mood changes and symptoms of depression. When treatment conditions were analyzed as a function of psychiatric comorbidity, patients with current major depression showed the greatest mecamylamine-related improvements.103 In summary, these preliminary findings with mecamylamine support the hypothesis that antidepressants may be efficacious, in part, through inhibition of nAChRs.


This paper reviews the evidence that many antidepressants function as nAChR antagonists at physiologically relevant concentrations. In addition, the authors provide a working hypothesis for how this pharmacological property contributes to the efficacy of antidepressants. Preliminary evidence that mecamylamine, a potent nicotinic receptor antagonist devoid of monoamine reuptake inhibition, may reduce depression lends some clinical support to this hypothesis. With this in mind, future preclinical and clinical research is warranted to investigate the therapeutic potential of selective nicotinic receptor antagonists for the treatment of mood disorders.


There are several limitations to the hypothesis that nAChR inhibition contributes to the efficacy of many antidepressants. First, while bupropion27 and nortriptyline,111 like mecamylamine,26 have been shown to be effective smoking cessation aids, clinical studies with other antidepressants have failed to show efficacy for smoking cessation.112,113 One explanation for this discrepancy is that different nAChR subtypes are involved with nicotine dependency and mood modulation, and most antidepressants affect those involved with mood modulation, but only a few also affect nAChR subtypes involved with nicotine dependency. Future studies should characterize the pharmacology of antidepressants across all known nAChR subtypes and compare these data with antidepressant efficacy as smoking cessation medications in order to deduce which subtypes might be involved with each therapeutic endpoint.

Second, the finding that β2 subunit knockout mice show enhanced learned helplessness55 is difficult to reconcile with the hypothesis that nAChR inhibition improves mood. One possibility is that normal mood states require an optimal amount of nAChR neurotransmission and that either too much or too little could result in dysfunctional mood states. Moreover, excessive rapid switching between nAChR activation and inactivation could lead to mood instability. At the concentrations of antidepressants that affect nAChRs, it is unlikely that complete receptor inhibition occurs, thus, allowing for a range of necessary neurotransmission, but with reduced potential for overstimulation during stressful situations. In this regard, it is noteworthy that in the controlled mecamylamine trial for TD, mecamylamine affected mood differently depending on the severity of illness.110 For example, while those treated with mecamylamine who had moderate to severe TD exhibited improvements in mood, those with mild TD severity actually showed a trend toward worsening of mood and enhanced mood instability. Patients treated with placebo, however, had no significant change in mood regardless of illness severity.110 Similar state-dependent effects of nicotinic receptor modulating drugs are common and have been recently reviewed.114

Third, while suggestive, the clinical data regarding the putative mood modulating effects of mecamylamine remain preliminary due to the small number of patients tested so far.102,103 Thus, further rigorous investigation in more diverse affective disorder populations is needed before definitive conclusions can be drawn. In addition, it will be important to determine if mecamylamine acts primarily as an antidepressant, mood stabilizer, or both. If mecamylamine has mood stabilizing properties, the question remains as to why established antidepressants with nAChR inhibitory properties fail to stabilize mood and in fact can precipitate mania and induce rapid cycling in some patients with affective disorders? One possibility is that the monoaminergic elevating properties of most antidepressants are responsible for the increased risk of switching to mania. With this in mind, it is interesting to note that bupropion, which is a fairly potent and selective nicotinic receptor antagonist,23 having relatively less monoaminergic elevating effects than other antidepressants, is often considered the least likely of all antidepressants to precipitate mania.115,116 While not addressed specifically in this paper, other established and putative mood stabilizers (without enhanced monoaminergic effects) such as carbamazepine, nimodipine, and diltiazem also inhibit certain nAChRs at clinically relevant concentrations.117,118 One potential way that nicotinic receptor antagonists could stabilize mood is by moderating the effects of light on the circadian rhythm, as has been found with mecamylamine.98,99

Fourth, as mentioned earlier, a growing body of preclinical evidence suggests that many antidepressants have important downstream neurotropic effects, such as enhanced neurogenesis in adult rat hippocampus.119 These findings raise the possibility that increased cell proliferation and increased neuronal number may be a mechanism by which antidepressant treatment overcomes the stress-induced atrophy and loss of hippocampal neurons and may contribute to the therapeutic actions of antidepressant treatment.9,10 The question remains as to what role inhibition of nAChR by antidepressants may play in contributing to these therapeutic effects of chronic antidepressant exposure? Numerous studies have demonstrated that compounds interacting with nAChRs have, both in vivo and in vitro, the potential to be neuroprotective.120 Epidemiological and clinical studies suggest also a potential neuroprotective/ trophic role of nicotine in neurodegenerative disease, such as Alzheimer's and Parkinson's disease.121 Taken together experimental and clinical data largely indicate a neuroprotective/trophic role of nAChR modulation involving mainly α4, β2- and α7-nAChR subtypes.120,122,123,124,125,126,127,128 While it is clear that some level of nAChR activation is required for these neuroprotective/trophic effects to occur, it is also clear that overstimulation of certain nAChR subunits, such as α7 can lead to cytotoxicity.129,130 In fact, many of the neuroprotective nAChR ligands, including nicotine, have been characterized as partial agonists allowing for only a percentage of the current that would be achieved by full ACh-induced nAChR activation.130,131,132,133 Therefore, weak to moderate inhibitory actions of antidepressants at nAChRs under hypercholinergic conditions might result in significantly improved steady-state nAChR activation, while limiting the amount of receptor-mediated calcium flux which would prevent the sort of excessive cytotoxic activation seen, for example, when NMDA-type glutamate receptors are overstimulated.

Thus, there are several concepts to ponder when choosing therapies and avenues for discovery of new antidepressant medications. There are strengths to the monoamine hypothesis of depression in the clear and potent effects of antidepressant medications as inhibitors of monoamine uptake and in the clinical utility of antidepressants in therapy. Recent functional anatomic findings point to changes in neuronal circuitry in the etiology and in the treatment of depression, lending support to a neural plasticity model of anxiety, depression, and their treatment. The notion of mood normalization as a therapeutic goal and the established efficacy of antidepressants and mood stabilizers suggest the existence of mood set-points that are delicately affected by neurochemical balance and perhaps controlled and controllable via chemical inertial reels that allow gentle sways in mood but brace against radical swings in emotion. The cholinergic hypothesis of depression as elaborated here should be considered as an adjunct rather than an absolute alternative to these other ideas, in part because there are clear conjunctions between it and the other ideas. For example, nAChR activity modulates the release of monoamines, and nAChRs are plausible targets of at least some proven antidepressants at clinically effective concentrations. Nicotinic receptor activity is involved not only in direct excitatory neurotransmission, but also in the regulation of neurotransmission by modulating neurotransmitter release and by affecting neurite outgrowth and architecture of neuronal connections.65 At the same time, the balance between nAChR activation, desensitization, and persistent inactivation may be a substrate for circuit and signaling stabilization, which seems to be a critical feature in the control of mood. Therefore, whether or not nAChR are central to mood control, they seem to contribute to it (as shown in Figure 2), and consideration of their roles is likely to hasten an improved understanding of mood and its management.

Figure 2

Nicotinic receptor modulation of neural circuits regulating mood.

Future directions

Based on the evidence in support of the hypothesis that nAChR inhibition may reduce depression and stabilize mood, future research is clearly warranted to fully investigate the therapeutic potential of nicotinic receptor antagonists as a novel approach to treating affective disorders. This would include complete profiling of all antidepressants across all known nAChR subtypes, testing for both inhibition as well as the possibility of partial agonist effects or allosteric modulation at even lower concentrations than previously tested.

Several lead compounds are now under active development including an isomer of mecamylamine with prolonged inhibitory properties at human nAChRs and potentially fewer side-effects,134 as well as third generation compounds with very selective and potent inhibitory properties at various nAChR subunits.135,139 Development of these compounds as smoking cessation medications followed by post-approval investigation of their mood modulating potential may be a prudent research and development model to follow.


  1. 1

    Schildkraut JJ . The catecholamine hypothesis of affective disorders: a review of supporting evidence, Am J Psychiatry 1965 122: 509–522

    CAS  Google Scholar 

  2. 2

    Coppen A . The biochemistry of affective disorders Br J Psychiatry 1967 113: 1237–1264

    CAS  Google Scholar 

  3. 3

    Feighner JP . Mechanism of action of antidepressant medications J Clin Psychiatry 1999 60: 4–11 discussion 12–13

    CAS  PubMed  Google Scholar 

  4. 4

    Gittos MW . Toward a better understanding of depression: new mechanistic considerations of antidepressant action provide a basis for development of delay-free drugs Drug Devel Res 2000 51: 1–6

    CAS  Google Scholar 

  5. 5

    Gjerris A, Sorensen AS, Rafaelsen OJ, Werdelin L, Alling C, Linnoila M . 5-HT and 5-HIAA in cerebrospinal fluid in depression J Affect Disord 1987 12: 13–22

    CAS  PubMed  Google Scholar 

  6. 6

    Clerc G, Noury J, Gittos M . Antidepressant effect of a tryptophan hydroxylase activation inhibitor, AGN 2979 Am J Psychiatry 1986 143: 264–265

    CAS  PubMed  Google Scholar 

  7. 7

    Mennini T, Mocaer E, Garattini S . Tianeptine, a selective enhancer of serotonin uptake in rat brain Naunyn Schmiedebergs Arch Pharmacol 1987 336: 478–482

    CAS  PubMed  Google Scholar 

  8. 8

    Gershon S, Hekimian LJ, Floyd A . Non-correlation of preclinical-clinical evaluation of a prosposed anti-depressant 4-phenyl-bicyclo(2,2,2)octan-1-amine hydrochloride monohydrate (EXP 561) Arzneimittelforschung 1968 18: 243–245

    CAS  PubMed  Google Scholar 

  9. 9

    Duman RS, Heninger GR, Nestler EJ . A molecular and cellular theory of depression Arch Gen Psychiatry 1997 54: 597–606

    CAS  PubMed  PubMed Central  Google Scholar 

  10. 10

    Duman RS, Malberg J, Nakagawa S, D'Sa C . Neuronal plasticity and survival in mood disorders Biol Psychiatry 2000 48: 732–739

    CAS  Google Scholar 

  11. 11

    Eldefrawi ME, Warnick JE, Schofield GG, Albuquerque EX, Eldefrawi AT . Interaction of imipramine with the ionic channel of the acetylcholine receptor of motor endplate and electric organ Biochem Pharmacol 1981 30: 1391–1394

    CAS  PubMed  Google Scholar 

  12. 12

    Arita M, Wada A, Takara H, Izumi F . Inhibition of 22Na influx by tricyclic and tetracyclic antidepressants and binding of [3H]imipramine in bovine adrenal medullary cells J Pharmacol Exp Ther 1987 243: 342–348

    CAS  PubMed  Google Scholar 

  13. 13

    Izaguirre V, Fernandez-Fernandez JM, Cena V, Gonzalez-Garcia C . Tricyclic antidepressants block cholinergic nicotinic receptors and ATP secretion in bovine chromaffin cells FEBS Lett 1997 418: 39–42

    CAS  PubMed  Google Scholar 

  14. 14

    Schofield GG, Witkop B, Warnick JE, Albuquerque EX . Differentiation of the open and closed states of the ionic channels of nicotinic acetylcholine receptors by tricyclic antidepressants Proc Natl Acad Sci USA 1981 78: 5240–5244

    CAS  PubMed  Google Scholar 

  15. 15

    Park TJ, Shin SY, Suh BC, Suh EK, Lee IS, Kim YS, Kim KT . Differential inhibition of catecholamine secretion by amitriptyline through blockage of nicotinic receptors, sodium channels, and calcium channels in bovine adrenal chromaffin cells Synapse 1998 29: 248–256

    CAS  PubMed  Google Scholar 

  16. 16

    Rana B, McMorn SO, Reeve HL, Wyatt CN, Vaughan PF, Peers C . Inhibition of neuronal nicotinic acetylcholine receptors by imipramine and desipramine Eur J Pharmacol 1993 250: 247–251

    CAS  PubMed  Google Scholar 

  17. 17

    Garcia-Colunga J, Awad JN, Miledi R . Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac) Proc Natl Acad Sci USA 1997 94: 2041–2044

    CAS  PubMed  Google Scholar 

  18. 18

    Hennings EC, Kiss JP, Vizi ES . Nicotinic acetylcholine receptor antagonist effect of fluoxetine in rat hippocampal slices Brain Res 1997 759: 292–294

    CAS  PubMed  Google Scholar 

  19. 19

    Maggi L, Palma E, Miledi R, Eusebi F . Effects of fluoxetine on wild and mutant neuronal alpha 7 nicotinic receptors Mol Psychiatry 1998 3: 350–355

    CAS  PubMed  Google Scholar 

  20. 20

    Fryer JD, Lukas RJ . Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function J Neurochem 1999 72: 1117–1124

    CAS  PubMed  Google Scholar 

  21. 21

    Hennings EC, Kiss JP, De Oliveira K, Toth PT, Vizi ES . Nicotinic acetylcholine receptor antagonistic activity of monoamine uptake blockers in rat hippocampal slices J Neurochem 1999 73: 1043–1050

    CAS  PubMed  Google Scholar 

  22. 22

    Kiss JP, Hennings EC, De Oliveira K, Toth PT, Vizi ES . Nicotinic acetylcholine receptor antagonistic activity of the selective dopamine uptake blocker GBR-12909 in rat hippocampal slices J Physiol 2000 526: 69P

    Google Scholar 

  23. 23

    Slemmer JE, Martin BR, Damaj MI . Bupropion is a nicotinic antagonist J Pharmacol Exp Ther 2000 295: 321–327

    CAS  PubMed  Google Scholar 

  24. 24

    Fryer JD, Lukas RJ . Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine J Pharmacol Exp Ther 1999 288: 88–92

    CAS  PubMed  Google Scholar 

  25. 25

    Martin BR, Onaivi ES, Martin TJ . What is the nature of mecamylamine's antagonism of the central effects of nicotine? Biochem Pharmacol 1989 38: 3391–3397

    CAS  PubMed  Google Scholar 

  26. 26

    Rose JE, Behm FM, Westman EC . Nicotine-mecamylamine treatment for smoking cessation: the role of pre- cessation therapy Exp Clin Psychopharmacol 1998 6: 331–343

    CAS  PubMed  Google Scholar 

  27. 27

    Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC et al. A comparison of sustained-release bupropion and placebo for smoking cessation N Engl J Med 1997 337: 1195–1202

    CAS  Google Scholar 

  28. 28

    Mitchell AJ . The role of corticotropin releasing factor in depressive illness: a critical review Neurosci Biobehav Rev 1998 22: 635–651

    CAS  PubMed  Google Scholar 

  29. 29

    Nemeroff CB . The neurobiology of depression Sci Am 1998 278: 42–49

    CAS  PubMed  Google Scholar 

  30. 30

    Gilad GM . The stress-induced response of the septo-hippocampal cholinergic system. A vectorial outcome of psychoneuroendocrinological interactions Psychoneuroendocrinology 1987 12: 167–184

    CAS  PubMed  Google Scholar 

  31. 31

    Janowsky DS, Risch SC . Cholinomimetic and anticholinergic drugs used to investigate and acetylcholine hypothesis of affective disorders and stress Drug Devel Res 1984 4: 125–142

    CAS  Google Scholar 

  32. 32

    Janowsky DS, el-Yousef MK, Davis JM, Sekerke HJ . A cholinergic-adrenergic hypothesis of mania and depression Lancet 1972 2: 632–635

    CAS  Google Scholar 

  33. 33

    Janowsky DS, Overstreet DH, Nurnberger JI Jr . Is cholinergic sensitivity a genetic marker for the affective disorders? Am J Med Genet 1994 54: 335–344

    CAS  PubMed  Google Scholar 

  34. 34

    Janowsky D, El-Yousef MK, Davis JM . Acetylcholine and depression Psychosom Med 1974 36: 248–257

    CAS  PubMed  Google Scholar 

  35. 35

    Nurnberger JI Jr, Jimerson DC, Simmons-Alling S, Tamminga C, Nadi NS, Lawrence D et al. Behavioral, physiological, and neuroendocrine responses to arecoline in normal twins and bipolar patients Psychiatry Res 1983 9: 191–200

    PubMed  Google Scholar 

  36. 36

    Risch SC, Kalin NH, Murphy DL . Pharmacological challenge strategies: implications for neurochemical mechanisms in affective disorders and treatment approaches J Clin Psychopharmacol 1981 1: 238–243

    CAS  PubMed  Google Scholar 

  37. 37

    Oppenheimer G, Ebstein RP, Belmaker RH . Effect of lithium on the physostigmine-induced behavioral syndrome and plasma cyclic GMP J Psychiatr Res 1979 15: 133–138

    Google Scholar 

  38. 38

    Janowsky DS, Overstreet DH, Nurnberger JI Jr . Is cholinergic sensitivity a genetic marker for the affective disorders? Am J Med Genet 1994 54: 335–344

    CAS  PubMed  Google Scholar 

  39. 39

    Charles HC, Lazeyras F, Krishnan KR, Boyko OB, Payne M, Moore D . Brain choline in depression: in vivo detection of potential pharmacodynamic effects of antidepressant therapy using hydrogen localized spectroscopy Prog Neuropsychopharmacol Biol Psychiatry 1994 18: 1121–1127

    CAS  PubMed  Google Scholar 

  40. 40

    Steingard RJ, Yurgelun-Todd DA, Hennen J, Moore JC, Moore CM, Vakili K et al. Increased orbitofrontal cortex levels of choline in depressed adolescents as detected by in vivo proton magnetic resonance spectroscopy Biol Psychiatry 2000 48: 1053–1061

    CAS  Google Scholar 

  41. 41

    Kile JP, Turner BB . Serotonergic and cholinergic interaction in the regulation of pituitary-adrenal function in rats Experientia 1985 41: 1123–1127

    CAS  PubMed  Google Scholar 

  42. 42

    Rhodes ME, O'Toole SM, Wright SL, Czambel RK, Rubin RT . Sexual diergism in rat hypothalamic-pituitary-adrenal axis responses to cholinergic stimulation and antagonism Brain Res Bull 2001 54: 101–113

    CAS  PubMed  Google Scholar 

  43. 43

    Parrott AC . Stress modulation over the day in cigarette smokers Addiction 1995 90: 233–244

    CAS  PubMed  Google Scholar 

  44. 44

    Glassman AH, Helzer JE, Cove LS, Cottler LB, Stetner F, Tipp JE et al. Smoking, smoking cessation, and major depression Jama 1990 264: 1546–1549

    CAS  Google Scholar 

  45. 45

    Bergen AW, Caporaso N . Cigarette smoking J Natl Cancer Inst 1999 91: 1365–1375

    CAS  Google Scholar 

  46. 46

    Anda RF, Williamson DF, Escobedo LG, Mast EE, Giovino GA, Remington PL . Depression and the dynamics of smoking. A national perspective Jama 1990 264: 1541–1545

    CAS  Google Scholar 

  47. 47

    Covey LS, Glassman AH, Stetner F . Cigarette smoking and major depression J Addict Dis 1998 17: 35–46

    CAS  Google Scholar 

  48. 48

    Covey LS, Glassman AH, Stetner F . Major depression following smoking cessation Am J Psychiatry 1997 154: 263–265

    CAS  Google Scholar 

  49. 49

    Labbate LA . Nicotine cessation, mania, and depression [letter] [published erratum appears in Am J Psychiatry 1992 Sep; 149(9): 1287] Am J Psychiatry 1992 149: 708

    CAS  PubMed  Google Scholar 

  50. 50

    Salin-Pascual RJ, Rosas M, Jimenez-Genchi A, Rivera-Meza BL, Delgado-Parra V . Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression J Clin Psychiatry 1996 57: 387–389

    CAS  PubMed  Google Scholar 

  51. 51

    Tizabi Y, Overstreet DH, Rezvani AH, Louis VA, Clark E Jr, Janowsky DS et al. Antidepressant effects of nicotine in an animal model of depression Psychopharmacol (Berl) 1999 142: 193–199

    CAS  Google Scholar 

  52. 52

    Semba J, Mataki C, Yamada S, Nankai M, Toru M . Antidepressantlike effects of chronic nicotine on learned helplessness paradigm in rats Biol Psychiatry 1998 43: 389–391

    CAS  PubMed  Google Scholar 

  53. 53

    Ferguson SM, Brodkin JD, Lloyd GK, Menzaghi F . Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression Psychopharmacol (Berl) 2000 152: 295–303

    CAS  Google Scholar 

  54. 54

    Tizabi Y, Rezvani AH, Russell LT, Tyler KY, Overstreet DH . Depressive characteristics of FSL rats: involvement of central nicotinic receptors Pharmacol Biochem Behav 2000 66: 73–77

    CAS  PubMed  Google Scholar 

  55. 55

    Caldarone BJ, Picciotto MR . Role of high affinity nicotinic receptors in learned helplessness behavior Soc Neurosci 1999 Miami, FL

    Google Scholar 

  56. 56

    Wang MQ, Fitzhugh EC, Green BL, Turner LW, Eddy JM, Westerfield RC . Prospective social-psychological factors of adolescent smoking progression J Adolesc Health 1999 24: 2–9

    CAS  PubMed  Google Scholar 

  57. 57

    Patton GC, Hibbert M, Rosier MJ, Carlin JB, Caust J, Bowes G . Is smoking associated with depression and anxiety in teenagers? Am J Public Health 1996 86: 225–230

    CAS  PubMed  PubMed Central  Google Scholar 

  58. 58

    Patton GC, Carlin JB, Coffey C, Wolfe R, Hibbert M, Bowes G . Depression, anxiety, and smoking initiation: a prospective study over 3 years Am J Public Health 1998 88: 1518–1522

    CAS  PubMed  PubMed Central  Google Scholar 

  59. 59

    Goodman E, Capitman J . Depressive symptoms and cigarette smoking among teens Pediatrics 2000 106: 748–755

    CAS  PubMed  Google Scholar 

  60. 60

    Breslau N, Klein DF . Smoking and panic attacks: an epidemiologic investigation Arch Gen Psychiatry 1999 56: 1141–1147

    CAS  PubMed  Google Scholar 

  61. 61

    Brown RA, Lewinsohn PM, Seeley JR, Wagner EF . Cigarette smoking, major depression, and other psychiatric disorders among adolescents J Am Acad Child Adolesc Psychiatry 1996 35: 1602–1610

    CAS  PubMed  Google Scholar 

  62. 62

    Kendler KS, Neale MC, MacLean CJ, Heath AC, Eaves LJ, Kessler RC . Smoking and major depression. A causal analysis Arch Gen Psychiatry 1993 50: 36–43

    CAS  Google Scholar 

  63. 63

    Perkins KA . Baseline-dependency of nicotine effects: a review Behav Pharmacol 1999 10: 597–615

    CAS  PubMed  Google Scholar 

  64. 64

    Dani JA . Overview of nicotinic receptors and their roles in the central nervous system Biol Psychiatry 2001 49: 166–174

    CAS  PubMed  Google Scholar 

  65. 65

    Lukas RJ . Neuronal nicotinic aceytlcholine receptors. The Nicotinic Acetylcholine Receptor: Current Views and Future Trends Springer-Verlag, Berlin and RG Landes Co 1998

    Google Scholar 

  66. 66

    Colquhoun LM, Patrick JW . Pharmacology of neuronal nicotinic acetylcholine receptor subtypes Adv Pharmacol 1997 39: 191–220

    CAS  PubMed  Google Scholar 

  67. 67

    Lukas RJ et al. International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits Pharmacol Rev 1999 51: 397–401

    CAS  PubMed  Google Scholar 

  68. 68

    Conroy WG, Berg DK . Neurons can maintain multiple classes of nicotinic acetylcholine receptors distinguished by different subunit compositions J Biol Chem 1995 270: 4424–4431

    CAS  PubMed  Google Scholar 

  69. 69

    Vizi ES, Lendvai B . Modulatory role of presynaptic nicotinic receptors in synaptic and non-synaptic chemical communication in the central nervous system Brain Res Brain Res Rev 1999 30: 219–235

    CAS  PubMed  Google Scholar 

  70. 70

    Picciotto MR, Caldarone BJ, King SL, Zachariou V . Nicotinic receptors in the brain. Links between molecular biology and behavior Neuropsychopharmacology 2000 22: 451–465

    CAS  PubMed  Google Scholar 

  71. 71

    Lukas RJ, Ke L, Bencherif M, Eisenhour CM . Regulation by nicotine of its own receptors Drug Devel Res 1996 38: 136–148

    CAS  Google Scholar 

  72. 72

    Hsu YN, Amin J, Weiss DS, Wecker L . Sustained nicotine exposure differentially affects alpha 3 beta 2 and alpha 4 beta 2 neuronal nicotinic receptors expressed in Xenopus oocytes J Neurochem 1996 66: 667–675

    CAS  PubMed  Google Scholar 

  73. 73

    Benowitz NL . Pharmacokinetic considerations in understanding nicotine dependence Ciba Found Symp 1990 152: 186–200 discussion 200–209

    CAS  PubMed  Google Scholar 

  74. 74

    Dani JA, Radcliffe KA, Pidoplichko VI . Variations in desensitization of nicotinic acetylcholine receptors from hippocampus and midbrain dopamine areas Eur J Pharmacol 2000 393: 31–38

    CAS  PubMed  Google Scholar 

  75. 75

    Benwell ME, Balfour DJ, Birrell CE . Desensitization of the nicotine-induced mesolimbic dopamine responses during constant infusion with nicotine Br J Pharmacol 1995 114: 454–460

    CAS  PubMed  PubMed Central  Google Scholar 

  76. 76

    Hulihan-Giblin BA, Lumpkin MD, Kellar KJ . Effects of chronic administraion of nicotine on prolactin release in the rat: inactivation of prolactin response by repeated injections of nicotine J Pharmacol Exp Therapeut 1989 252: 21–25

    Google Scholar 

  77. 77

    Wada E, Wada K, Boulter J, Deneris E, Heinemann S, Patrick J et al. Distribution of alpha 2, alpha 3, alpha 4, and beta 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat J Comp Neurol 1989 284: 314–335

    CAS  Google Scholar 

  78. 78

    Clarke PB, Schwartz RD, Paul SM, Pert CB, Pert A . Nicotinic binding in rat brain: autoradiographic comparison of [3H]acetylcholine, [3H]nicotine, and [125I]-alpha-bungarotoxin J Neurosci 1985 5: 1307–1315

    CAS  PubMed  Google Scholar 

  79. 79

    Mulle C, Vidal C, Benoit P, Changeux JP . Existence of different subtypes of nicotinic acetylcholine receptors in the rat habenulo-interpeduncular system J Neurosci 1991 11: 2588–2597

    CAS  PubMed  Google Scholar 

  80. 80

    Quick MW, Ceballos RM, Kasten M, McIntosh JM, Lester RA . Alpha3beta4 subunit-containing nicotinic receptors dominate function in rat medial habenula neurons Neuropharmacology 1999 38: 769–783

    CAS  PubMed  Google Scholar 

  81. 81

    Albuquerque EX, Alkondon M, Pereira EF, Castro NG, Schrattenholz A, Barbosa CT et al. Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function J Pharmacol Exp Ther 1997 280: 1117–1136

    CAS  PubMed  Google Scholar 

  82. 82

    Albuquerque EX, Pereira EF, Alkondon M, Schrattenholz A, Maelicke A . Nicotinic acetylcholine receptors on hippocampal neurons: distribution on the neuronal surface and modulation of receptor activity J Recept Signal Transduct Res 1997 17: 243–266

    CAS  PubMed  Google Scholar 

  83. 83

    Raber J, Koob GF, Bloom FE . Interleukin-2 (IL-2) induces corticotropin-releasing factor (CRF) release from the amygdala and involves a nitric oxide-mediated signaling; comparison with the hypothalamic response J Pharmacol Exp Ther 1995 272: 815–824

    CAS  PubMed  Google Scholar 

  84. 84

    Okuda H, Shioda S, Nakai Y, Nakayama H, Okamoto M, Nakashima T . The presence of corticotropin-releasing factor-like immunoreactive synaptic vesicles in axon terminals with nicotinic acetylcholine receptor-like immunoreactivity in the median eminence of the rat Neurosci Lett 1993 161: 183–186

    CAS  PubMed  Google Scholar 

  85. 85

    Takada Y, Ihara H, Urano T, Takada A . Changes in blood and plasma serotonergic measurements in rats—effect of nicotine and/or exposure to different stresses Thromb Res 1995 80: 307–316

    CAS  PubMed  Google Scholar 

  86. 86

    Sithichoke N, Marotta SF . Cholinergic influences on hypothalamic-pituitary-adrenocortical activity of stressed rats: an approach utilizing agonists and antagonists Acta Endocrinol (Copenh) 1978 89: 726–736

    CAS  Google Scholar 

  87. 87

    Newman MB, Nazian S, Sanberg PR, Diamond D, Shytle RD . Corticosterone-attenutating and anxiolytic properties of mecamylamine in the rat Neuro-Psychopharmacol Biol Psychiatry 2001 25: 609–620

    CAS  Google Scholar 

  88. 88

    Houdi AA, Dowell RT, Diana JN . Cardiovascular responses to cigarette smoke exposure in restrained conscious rats J Pharmacol Exp Ther 1995 275: 646–653

    CAS  PubMed  Google Scholar 

  89. 89

    Kubo T, Katsumata Y . Fukumori R, Taguchi K, Hagiwara Y. Central nicotinic receptor blockade inhibits emotionally conditioned pressor responses in rats Experientia 1996 52: 348–352

    CAS  PubMed  Google Scholar 

  90. 90

    Corrigall WA, Coen KM . Selective dopamine antagonists reduce nicotine self-administration Psychopharmacology 1991 104: 171–176

    CAS  PubMed  PubMed Central  Google Scholar 

  91. 91

    Corrigall WA, Franklin KB, Coen KM, Clarke PB . The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine Psychopharmacology 1992 107: 285–289

    CAS  PubMed  PubMed Central  Google Scholar 

  92. 92

    Clarke PB, Fu DS, Jakubovic A, Fibiger HC . Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats J Pharmacol Exp Ther 1988 246: 701–708

    CAS  PubMed  Google Scholar 

  93. 93

    Pidoplichko VI, DeBiasi M, Williams JT, Dani JA . Nicotine activates and desensitizes midbrain dopamine neurons Nature 1997 390: 401–404

    CAS  PubMed  Google Scholar 

  94. 94

    Leibenluft E, Albert PS, Rosenthal NE, Wehr TA . Relationship between sleep and mood in patients with rapid-cycling bipolar disorder Psychiatry Res 1996 63: 161–168

    CAS  PubMed  Google Scholar 

  95. 95

    O'Hara BF, Edgar DM, Cao VH, Wiler SW, Heller HC, Kilduff TS et al. Nicotine and nicotinic receptors in the circadian system Psychoneuroendocrinology 1998 23: 161–173

    CAS  PubMed  Google Scholar 

  96. 96

    O'Hara BF, Macdonald E, Clegg D, Wiler SW, Andretic R, Cao VH et al. Developmental changes in nicotinic receptor mRNAs and responses to nicotine in the suprachiasmatic nucleus and other brain regions Brain Res Mol Brain Res 1999 66: 71–82

    CAS  PubMed  Google Scholar 

  97. 97

    Cirelli C, Tononi G . Gene expression in the brain across the sleep-waking cycle Brain Res 2000 885: 303–321

    CAS  PubMed  Google Scholar 

  98. 98

    Keefe DL, Earnest DJ, Nelson D, Takahashi JS, Turek FW . A cholinergic antagonist, mecamylamine, blocks the phase-shifting effects of light on the circadian rhythm of locomotor activity in the golden hamster Brain Res 1987 403: 308–312

    CAS  PubMed  Google Scholar 

  99. 99

    Zhang Y, Zee PC, Kirby JD, Takahashi JS, Turek FW . A cholinergic antagonist, mecamylamine, blocks light-induced fos immunoreactivity in specific regions of the hamster suprachiasmatic nucleus Brain Res 1993 615: 107–112

    CAS  PubMed  Google Scholar 

  100. 100

    Patten CA, Choi WS, Gillin JC, Pierce JP . Depressive symptoms and cigarette smoking predict development and persistence of sleep problems in US adolescents Pediatrics 2000 106: E23

    CAS  PubMed  Google Scholar 

  101. 101

    Wetter DW, Carmack CL, Anderson CB, Moore CA, De Moor CA, Cinciripini PM et al. Tobacco withdrawal signs and symptoms among women with and without a history of depression Exp Clin Psychopharmacol 2000 8: 88–96

    CAS  PubMed  Google Scholar 

  102. 102

    Shytle RD, Silver AA, Sanberg PR . Comorbid bipolar disorder in tourette syndrome responds to nicotinic receptor antagonist, mecamylamine (Inversine® Biol Psychiatry 2000 48: 1028–1031

    CAS  PubMed  Google Scholar 

  103. 103

    Shytle RD, Silver AA, Sheehan KH, Sheehan DV, Sanberg PR . Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine Depression and Anxiety 2001 (in press)

  104. 104

    Shytle RD, Silver AA, Wilkinson BJ, Newman MB, Katherine-Philip M, Sanberg PR et al. Treatment of Tourette disorder with transdermal nicotine and haloperidol. In: IBC's 2nd International Symposium on Nicotinic Acetylcholine Receptors, Advances in Molecular Pharmacology and Drug Development Annapolis, MD 1999

    Google Scholar 

  105. 105

    Shytle RD, Silver AA, Philipp MK, McConville BJ, Sanberg PR . Transdermal nicotine for tourette's syndrome Drug Devel Res 1996 38: 290–298

    CAS  Google Scholar 

  106. 106

    Sanberg PR, Shytle RD, Silver AA . Treatment of Tourette's syndrome with mecamylamine [letter] Lancet 1998 352: 705–706

    CAS  PubMed  Google Scholar 

  107. 107

    Young JM, Shytle RD, Sanberg PR, George TP . Mecamylamine: new therapeutic uses and toxicity/risk profile Clin Ther 2001 23: 532–565

    CAS  PubMed  Google Scholar 

  108. 108

    Reid MS, Mickalian JD, Delucchi KL, Berger SP . A nicotine antagonist, mecamylamine, reduces cue-induced cocaine craving in cocaine-dependent subjects Neuropsychopharmacology 1999 20: 297–307

    CAS  PubMed  Google Scholar 

  109. 109

    Blomqvist O, Ericson M, Engel JA, Soderpalm B . Accumbal dopamine overflow after ethanol: localization of the antagonizing effect of mecamylamine Eur J Pharmacol 1997 334: 149–156

    CAS  PubMed  Google Scholar 

  110. 110

    Silver AA, Shytle RD, Sheehan KH, Sheehan DV, Ramos A, Sanberg PR . Multi-center double blind placebo controlled study of mecamylamine monotherapy for Tourette's disorder J Am Acad Child Adolesc Psychiatry 2001 40: 1103–1110

    CAS  PubMed  Google Scholar 

  111. 111

    Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D . A randomized trial of nortriptyline for smoking cessation Arch Intern Med 1998 158: 2035–2039

    CAS  PubMed  Google Scholar 

  112. 112

    Hughes JR, Stead LF, Lancaster T . Antidepressants for smoking cessation (Cochrane Review) Cochrane Database Syst Rev 2000 4: CD000031

    Google Scholar 

  113. 113

    Dalack GW, Glassman AH, Rivelli S, Covey L, Stetner F . Mood, major depression, and fluoxetine response in cigarette smokers Am J Psychiatry 1995 152: 398–403

    CAS  PubMed  Google Scholar 

  114. 114

    Perkins KA . Individual variability in responses to nicotine Behav Genet 1995 25: 119–132

    CAS  PubMed  Google Scholar 

  115. 115

    Compton MT, Nemeroff CB . The treatment of bipolar depression J Clin Psychiatry 2000 61: 57–67

    CAS  PubMed  Google Scholar 

  116. 116

    Thase ME, Sachs GS . Bipolar depression: pharmacotherapy and related therapeutic strategies Biol Psychiatry 2000 48: 558–572

    CAS  PubMed  Google Scholar 

  117. 117

    Picard F, Bertrand S, Steinlein OK, Bertrand D . Mutated nicotinic receptors responsible for autosomal dominant nocturnal frontal lobe epilepsy are more sensitive to carbamazepine Epilepsia 1999 40: 1198–1209

    CAS  PubMed  Google Scholar 

  118. 118

    Donnelly-Roberts DL, Arneric SP, Sullivan JP . Functional modulation of human “ganglionic-like” neuronal nicotinic acetylcholine receptors (nAChRs) by L-type calcium channel antagonists Biochem Biophys Res Commun 1995 213: 657–662

    CAS  PubMed  Google Scholar 

  119. 119

    Malberg JE, Eisch AJ, Nestler EJ, Duman RS . Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus J Neurosci 2000 20: 9104–9110

    CAS  Google Scholar 

  120. 120

    Belluardo N, Mudo G, Blum M, Fuxe K . Central nicotinic receptors, neurotrophic factors and neuroprotection Behav Brain Res 2000 113: 21–34

    CAS  PubMed  Google Scholar 

  121. 121

    James JR, Nordberg A . Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: emphasis on Alzheimer's disease and Parkinson's disease Behav Genet 1995 25: 149–159

    CAS  Google Scholar 

  122. 122

    Ryan RE, Ross SA, Drago J, Loiacono RE . Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice Br J Pharmacol 2001 132: 1650–1656

    CAS  PubMed  PubMed Central  Google Scholar 

  123. 123

    Prendergast MA, Harris BR, Mayer S, Holley RC, Hauser KF, Littleton JM . Chronic nicotine exposure reduces N-methyl-D-aspartate receptor-mediated damage in the hippocampus without altering calcium accumulation or extrusion: evidence of calbindin-D28K overexpression Neuroscience 2001 102: 75–85

    CAS  PubMed  Google Scholar 

  124. 124

    Zoli M, Picciotto MR, Ferrari R, Cocchi D, Changeux JP . Increased neurodegeneration during ageing in mice lacking high-affinity nicotine receptors Embo J 1999 18: 1235–1244

    CAS  PubMed  PubMed Central  Google Scholar 

  125. 125

    O'Neill AB, Morgan SJ, Brioni JD . Histological and behavioral protection by (−)-nicotine against quinolinic acid-induced neurodegeneration in the hippocampus Neurobiol Learn Mem 1998 69: 46–64

    CAS  PubMed  Google Scholar 

  126. 126

    Kihara T, Shimohama S, Sawada H, Kimura J, Kume T, Kochiyama H, Maeda T . Akaike A. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity Ann Neurol 1997 42: 159–163

    CAS  PubMed  Google Scholar 

  127. 127

    Shimohama S, Akaike A, Kimura J . Nicotine-induced protection against glutamate cytotoxicity. Nicotinic cholinergic receptor-mediated inhibition of nitric oxide formation Ann NY Acad Sci 1996 777: 356–361

    CAS  PubMed  Google Scholar 

  128. 128

    Akaike A, Tamura Y, Yokota T, Shimohama S, Kimura J . Nicotine-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity Brain Res 1994 644: 181–187

    CAS  PubMed  Google Scholar 

  129. 129

    Li Y, Papke RL, He YJ, Millard WJ, Meyer EM . Characterization of the neuroprotective and toxic effects of alpha7 nicotinic receptor activation in PC12 cells Brain Res 1999 830: 218–225

    CAS  PubMed  Google Scholar 

  130. 130

    Papke RL, Meyer E, Nutter T, Uteshev VV . alpha7 Receptor-selective agonists and modes of alpha7 receptor activation Eur J Pharmacol 2000 393: 179–195

    CAS  PubMed  Google Scholar 

  131. 131

    Papke RL, Thinschmidt JS, Moulton BA, Meyer EM, Poirier A . Activation and inhibition of rat neuronal nicotinic receptors by ABT- 418 Br J Pharmacol 1997 120: 429–438

    CAS  PubMed  PubMed Central  Google Scholar 

  132. 132

    Briggs CA et al. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo Pharmacol Biochem Behav 1997 57: 231–241

    CAS  PubMed  Google Scholar 

  133. 133

    Briggs CA, McKenna DG . Activation and inhibition of the human alpha7 nicotinic acetylcholine receptor by agonists Neuropharmacology 1998 37: 1095–1102

    CAS  PubMed  Google Scholar 

  134. 134

    Papke RL, Sanberg PR, Shytle RD . Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes J Pharmacol Exp Ther 2001 297: 646–656

    CAS  PubMed  Google Scholar 

  135. 135

    Dwoskin LP, Wilkins LH, Pauly JR, Crooks PA . Development of a novel class of subtype-selective nicotinic receptor antagonist: pyridine-N-substituted nicotine analogs Ann NY Acad Sci 1999 868: 617–619

    CAS  PubMed  Google Scholar 

  136. 136

    Giniatullin RA, Sokolova EM, Di Angelantonio S, Skorinkin A, Talantova MV, Nistri A . Rapid relief of block by mecamylamine of neuronal nicotinic acetylcholine receptors of rat chromaffin cells in vitro: an electrophysiological and modeling study Mol Pharmacol 2000 58: 778–787

    CAS  PubMed  Google Scholar 

  137. 137

    Lukas RJ . Pharmacological distinctions between functional nicotinic acetylcholine receptors on the PC12 rat pheochromocytoma and the TE671 human medulloblastoma J Pharmacol Exp Ther 1989 251: 175–182

    CAS  PubMed  Google Scholar 

  138. 138

    Lukas RJ . Expression of ganglia-type nicotinic acetylcholine receptors and nicotinic ligand binding sites by cells of the IMR-32 human neuroblastoma clonal line J Pharmacol Exp Ther 1993 265: 294–302

    CAS  PubMed  Google Scholar 

  139. 139

    Gatto GJ, Letchworth SR, Bencherif M . Antidepressant-like effects of a sub-type selective neuronal nicotinic receptor ligand, TC-1707, in the Forced Swim Test Soc Neurosci Abs 2001 27: 488.10

    Google Scholar 

Download references

Author information



Corresponding author

Correspondence to R D Shytle.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Shytle, R., Silver, A., Lukas, R. et al. Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 7, 525–535 (2002).

Download citation


  • nicotinic
  • mechanism
  • antidepressant
  • cholinergic
  • depression

Further reading


Quick links